

Drug Coverage Decision for BC PharmaCare

About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

Details of Drug Reviewed

Drug	vanzacaftor/tezacaftor/deutivacaftor
Brand name	Alyftrek™
Dosage form(s)	vanzacaftor (as vanzacaftor calcium) 4 mg / tezacaftor 20 mg / deutivacaftor 50 mg film-coated tablets for oral use vanzacaftor (as vanzacaftor calcium) 10 mg / tezacaftor 50 mg / deutivacaftor 125 mg film-coated tablets for oral use
Manufacturer	Vertex Pharmaceuticals (Canada) Incorporated
Submission type	New Submission
Indication reviewed	For the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one <i>F508del</i> mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (<i>CFTR</i>) gene.
Canada's Drug Agency (CDA-AMC) Reimbursement Reviews	CDA-AMC recommended: to Reimburse with clinical criteria and/or conditions. Visit the CDA-AMC website for more details .
Ministry of Health (the Ministry) Review	The Ministry reviewed reports prepared by the CDA-AMC, including clinical and pharmacoeconomic evidence review material and the recommendations of the Canadian Drug Expert Committee (CDEC). The Ministry also considered patient input provided to CDEC from one patient group, as well as a budget impact assessment.
Drug Coverage Decision	Exceptional Coverage through the Expensive Drugs for Rare Diseases (EDRD) Process
Date	July 29, 2026
Reason(s)	Drug coverage decision is consistent with the CDEC recommendation.

- | | |
|--|---|
| | <ul style="list-style-type: none">• Evidence from two clinical trials suggests that vanzacaftor/tezacaftor/deutivacaftor has little to no difference in clinical outcomes important to patients when compared to elexacaftor/tezacaftor/ivacaftor (Trikafta®) in patients twelve years and older. Another study suggests that Alyftrek™ may have clinical benefits in those aged 6 to 11. Moreover, Alyftrek™ may provide clinically meaningful benefit to patients with CF caused by rare <i>CFTR</i> mutations.• The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which were able to address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money. |
|--|---|

The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent national organization called Canada's Drug Agency (CDA-AMC) provides evidence-based recommendations to public drug plans across Canada through its reimbursement review process. As part of the CDA-AMC's Clinical Reimbursement Review process, the Canadian Drug Expert Committee (CDEC) makes reimbursement recommendations for non-oncology pharmaceuticals to the participating federal, provincial, and territorial publicly funded drug plans. In developing its recommendations, the CDEC considers:

- whether the drug is safe and effective
- what the drug costs and whether funding it provides good value
- ethical considerations of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by considering:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the CDA-AMC
- the recommendations and reimbursement conditions of the CDEC
- if a Ministry Initiated review, the advice of an independent expert group called the Drug Benefit Council (DBC)
- BC-specific patient input collected through the Your Voice website
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug
- the outcomes of pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with manufacturers

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.